President Obama's recently proposed fiscal-year 2017 budget includes two new healthcare proposals: (1) requiring drug companies to disclose various production costs for specific drugs, including research and development costs; and (2) and allowing the HHS Secretary to negotiate with drug companies on certain high-cost drug prices under Medicare Part D. Read about these proposals, and drug-industry opposition to them, in this essay by David Lazarus.
Read all of the Administration's health-care proposals here.
